These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 11820065)
21. Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial). Ryuzaki M; Nakamoto H; Nishida E; Sone M; Nakajima S; Yoshimoto M; Suzuki Y; Itagaki K J Hypertens; 2007 Nov; 25(11):2352-8. PubMed ID: 17921832 [TBL] [Abstract][Full Text] [Related]
23. The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. Sierra C; Coca A Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1055-62. PubMed ID: 18793108 [TBL] [Abstract][Full Text] [Related]
24. Barnidipine: a step towards safer blood pressure control? Birkenhäger WH Int J Clin Pract Suppl; 2000 Nov; (114):1. PubMed ID: 11221288 [No Abstract] [Full Text] [Related]
25. Barnidipine: a new calcium channel blocker for hypertension treatment. Liau CS Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):207-13. PubMed ID: 15853594 [TBL] [Abstract][Full Text] [Related]
26. [Hypertension therapy with beta blocker plus diuretic. "We are at the point of leaving behind an era"]. Dahlöf B MMW Fortschr Med; 2005 Mar; 147(12):8. PubMed ID: 15832781 [No Abstract] [Full Text] [Related]
28. Treating high blood pressure in Africans with type 2 diabetes. Okoro EO; Oyejola BA Ethn Dis; 2004; 14(1):160-1. PubMed ID: 15002939 [No Abstract] [Full Text] [Related]
29. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. Fournier A; Messerli FH; Achard JM; Fernandez L J Am Coll Cardiol; 2004 Apr; 43(8):1343-7. PubMed ID: 15093864 [TBL] [Abstract][Full Text] [Related]
30. [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. Hoogenberg K; van der Tuin J Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2099-100. PubMed ID: 12448967 [TBL] [Abstract][Full Text] [Related]
31. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280 [TBL] [Abstract][Full Text] [Related]
32. Cutting it close. It's the right dose and the right drug--how can it be too much? Karch AM; Karch FE Am J Nurs; 2000 Jan; 100(1):23. PubMed ID: 10705835 [No Abstract] [Full Text] [Related]
33. Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. Saito I; Fujikawa K; Saruta T; Hypertens Res; 2008 Jul; 31(7):1399-405. PubMed ID: 18957811 [TBL] [Abstract][Full Text] [Related]
34. Treatment of complicated and uncomplicated hypertension with nifedipine in Palestine. Sweileh WM Saudi Med J; 2005 Jan; 26(1):78-83. PubMed ID: 15756358 [TBL] [Abstract][Full Text] [Related]
35. [The ACCOMPLISH trial: are results really unexpected?]. Waeber B; Feihl F Rev Med Suisse; 2009 Jan; 5(185):25-8. PubMed ID: 19216321 [TBL] [Abstract][Full Text] [Related]